Here, we analyzed ZDHHC17 function in recruiting MAP2K4 and JNK/p38 to build a signaling module for MAPK pathway activation, the relevance of this interaction for malignant GBM progression, and identified an inhibitor targeting the ZDHHC17-MAP2K4 module. Here, MAP2K4 is linked to glioblastoma.